Hinge Health
HNGE
105.78
-2.32
-2.15%
Hinge Health
US · HNGE
#1682 by market cap
Listed 2025
105.78
-2.32
-2.15%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 10.75, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 3 years
Latest year +50.58% YoY
Margins
- Gross margin
- 79.65%
- Operating margin
- -92.94%
- Net margin
- -72.14%
Key ratios & quality
- Altman Z-Scorei
- 10.75
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 292.73M | 390.40M | 587.86M |
| Gross profit | 194.18M | 299.90M | 468.22M |
| Selling & admin expenses | 214.64M | 230.97M | 646.46M |
| Research & development | 110.06M | 100.84M | 368.14M |
| Operating profit | -130.51M | -31.91M | -546.37M |
| Pretax profit | -108.55M | -11.26M | -527.26M |
| Tax | -405.00K | 677.00K | 998.00K |
| Net profit | -108.14M | -11.93M | -528.26M |
| Basic EPS | -2 | 0 | -8 |
| Diluted EPS | -1.58 | -0.15 | -7.77 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 139.10M | 154.21M | 170.73M | 182.31M | 212.82M | 234.97M |
| Gross profit | 97.76M | 126.20M | 144.03M | 154.23M | 183.95M | 204.33M |
| Selling & admin expenses | 398.47M | 100.37M | 84.02M | 91.83M | 109.45M | 116.53M |
| Research & development | 279.96M | 31.92M | 32.76M | 30.34M | 34.06M | 37.47M |
| Operating profit | -580.67M | -6.09M | 27.26M | 32.07M | 40.44M | 50.33M |
| Pretax profit | -575.98M | -1.64M | 32.22M | 35.94M | 44.43M | 53.72M |
| Tax | -326.00K | 206.00K | 122.00K | 814.00K | 740.00K | -3.68M |
| Net profit | -575.65M | -1.84M | 32.10M | 35.13M | 43.69M | 57.40M |
| Basic EPS | -13 | 0 | 0 | 0 | 1 | 1 |
| Diluted EPS | -13.10 | -0.02 | 0.37 | 0.41 | 0.52 | 0.66 |
Balance sheet
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total current assets | 529.88M | 583.45M | 533.90M |
| Cash & ST investments | 423.36M | 466.57M | 363.86M |
| Inventory | 13.29M | 10.87M | 15.64M |
| Total assets | 622.53M | 673.26M | 744.76M |
| Total current liabilities | 184.16M | 249.30M | 362.41M |
| Short-term debt | 4.64M | 3.81M | 4.22M |
| Long-term debt | -- | -- | -- |
| Total liabilities | 195,250,000.00 | 256,557,000.00 | 366,225,000.00 |
| Total equity | 427.28M | 416.70M | 378.54M |
| Retained earnings | -510.80M | -522.74M | -1.05B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 598.43M | 658.88M | 533.90M | 540.05M | 643.35M | 567.86M |
| Cash & ST investments | 413.26M | 480.03M | 363.86M | 315.87M | 389.39M | 294.66M |
| Inventory | 13.99M | 13.81M | 15.64M | 14.17M | 16.77M | 19.19M |
| Total assets | 693.65M | 769.80M | 744.76M | 728.77M | 827.40M | 874.08M |
| Total current liabilities | 314.08M | 357.08M | 362.41M | 414.48M | 481.44M | 544.71M |
| Short-term debt | 4.05M | 4.18M | 4.22M | 4.23M | 4.25M | 4.72M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 320,002,000.00 | 361,930,000.00 | 366,225,000.00 | 417,211,000.00 | 483,070,000.00 | 574,663,000.00 |
| Total equity | 373.65M | 407.87M | 378.54M | 311.56M | 344.33M | 299.42M |
| Retained earnings | -1.08B | -1.08B | -1.05B | -1.02B | -972.18M | -914.78M |
Cash flow
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -63.91M | 49.00M | 171.44M |
| Depreciation & amortization | 5.63M | 5.95M | 5.13M |
| Free cash flow | -68.52M | 45.23M | 165.38M |
| Dividends paid | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 190.65M |
| Ending cash balance | 237.47M | 302.59M | 209.80M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 20.23M | 82.40M | 63.89M | 43.08M | 101.41M | 114.60M |
| Depreciation & amortization | 1.34M | 1.26M | 1.22M | 1.17M | 1.06M | 2.22M |
| Free cash flow | 18.40M | 81.28M | 61.53M | 41.55M | 99.56M | 112.66M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 255.68M | 0 | -65.03M | -104.97M | -26.53M | -25.89M |
| Ending cash balance | 238.97M | 263.14M | 209.80M | 188.11M | 287.67M | 215.84M |
Returns & efficiency
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| ROE %i | -- | -- | -- |
| ROA %i | -17.37 | -1.84 | -59.81 |
| ROIC %i | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- |
| EBIT margin %i | -44.59 | -8.17 | -92.94 |
| FCF / sales %i | -- | 11.59 | 28.13 |
| Current ratioi | 2.88 | 2.34 | 1.47 |
| Quick ratioi | 2.55 | 2.04 | 1.19 |
| Debt / assetsi | 2.53 | 1.64 | 1.08 |
| LT debt / equityi | -- | -- | 2.14 |
| Interest coveragei | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -245.65 | -206.28 | -- | -- | 41.41 | 65.53 |
| ROA %i | -61.54 | -55.74 | -59.81 | -70.96 | 14.11 | 20.23 |
| ROIC %i | -232.32 | -197.70 | -- | -- | 40.18 | 60.42 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -114.49 | -103.43 | -92.94 | -81.60 | 13.01 | 18.74 |
| FCF / sales %i | 18.18 | 26.41 | 28.13 | 31.37 | 39.43 | 39.37 |
| Current ratioi | 1.91 | 1.85 | 1.47 | 1.30 | 1.34 | 1.04 |
| Quick ratioi | 1.63 | 1.59 | 1.19 | 1.04 | 1.07 | 0.81 |
| Debt / assetsi | 1.44 | 1.17 | 1.08 | 0.96 | 0.71 | 3.88 |
| LT debt / equityi | 3.41 | 2.33 | 2.14 | 2.45 | 0.47 | 9.74 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-11-20 20:02:33 · For reference only, not investment advice and not tailored to your situation.
Hinge Health discussion 0 comments